Your browser doesn't support javascript.
loading
Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.
Datta, Somenath; Kataria, Rama; Zhang, Jia-Yue; Moore, Savannah; Petitpas, Kaitlyn; Mohamed, Adam; Zahler, Nathan; Pollak, Martin R; Olabisi, Opeyemi A.
Afiliação
  • Datta S; Division of Nephrology and Duke Molecular Physiology Institute, Duke University, Durham, North Carolina.
  • Kataria R; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.
  • Zhang JY; Harvard Medical School, Boston, Massachusetts.
  • Moore S; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.
  • Petitpas K; Harvard Medical School, Boston, Massachusetts.
  • Mohamed A; Harvard Medical School, Boston, Massachusetts.
  • Zahler N; Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Pollak MR; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.
  • Olabisi OA; Harvard Medical School, Boston, Massachusetts.
J Am Soc Nephrol ; 31(9): 2083-2096, 2020 09.
Article em En | MEDLINE | ID: mdl-32675303
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteína L1 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apolipoproteína L1 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article